{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T11:21:50Z","timestamp":1792408910221,"version":"4.4.0"},"reference-count":63,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:00:00Z","timestamp":1697155200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.xcrm.2023.101280","type":"journal-article","created":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T10:27:58Z","timestamp":1699439278000},"page":"101280","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort B"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8554-1185","authenticated-orcid":false,"given":"Xiuning","family":"Le","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis G.","family":"Paz-Ares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Van Meerbeeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Viteri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Cabrera","family":"Galvez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egbert F.","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Garassino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remi","family":"Veillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Vicente","family":"Baz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Fuentes","family":"Pradera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Sereno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Kozuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Chul","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Soo","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Youn","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Hyoung","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Choon-Hee","family":"Son","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon Ji","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Stroh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilafruz","family":"Juraeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene","family":"Vioix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Bruns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Otto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Johne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul K.","family":"Paik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2023.101280_bib1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jtho.2016.10.014","article-title":"Targeting MET in lung cancer: Will expectations finally be MET?","volume":"12","author":"Drilon","year":"2017","journal-title":"J.\u00a0Thorac. Oncol."},{"key":"10.1016\/j.xcrm.2023.101280_bib2","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.2147\/OTT.S231257","article-title":"MET oncogene in non-small cell lung cancer: Mechanism of MET dysregulation and agents targeting the HGF\/c-MET axis","volume":"13","author":"Liang","year":"2020","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.xcrm.2023.101280_bib3","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.jtho.2021.02.010","article-title":"Crizotinib in Patients With MET-Amplified NSCLC","volume":"16","author":"Camidge","year":"2021","journal-title":"J.\u00a0Thorac. Oncol."},{"key":"10.1016\/j.xcrm.2023.101280_bib4","first-page":"81","article-title":"Role of mesenchymal-epithelial transition amplification in resistance to anti-epidermal growth factor receptor agents","volume":"3","author":"Califano","year":"2015","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.xcrm.2023.101280_bib5","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s41571-020-0377-z","article-title":"MET-dependent solid tumours \u2014 molecular diagnosis and targeted therapy","volume":"17","author":"Guo","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2023.101280_bib6","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jtho.2020.11.017","article-title":"Genetic Heterogeneity of MET-Aberrant NSCLC and Its Impact on the Outcome of Immunotherapy","volume":"16","author":"Kron","year":"2021","journal-title":"J.\u00a0Thorac. Oncol."},{"key":"10.1016\/j.xcrm.2023.101280_bib7","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1158\/1078-0432.CCR-14-0450","article-title":"MET amplification status in therapy-na\u00efve adeno- and squamous cell carcinomas of the lung","volume":"21","author":"Schildhaus","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2023.101280_bib8","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.jtho.2021.01.1609","article-title":"Heterogeneity in MET-Aberrant NSCLC","volume":"16","author":"Le","year":"2021","journal-title":"J.\u00a0Thorac. Oncol."},{"key":"10.1016\/j.xcrm.2023.101280_bib9","doi-asserted-by":"crossref","first-page":"603","DOI":"10.21037\/tlcr-19-339","article-title":"Top-level MET gene copy number gain defines a subtype of poorly differentiated pulmonary adenocarcinomas with poor prognosis","volume":"9","author":"Overbeck","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.xcrm.2023.101280_bib10","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa2002787","article-title":"Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer","volume":"383","author":"Wolf","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2023.101280_bib11","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1158\/1078-0432.CCR-15-2061","article-title":"MET amplification and exon 14 splice site mutation define unique molecular subgroups of non-small cell lung carcinoma with poor prognosis","volume":"22","author":"Tong","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2023.101280_bib12","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1200\/JCO.2008.19.1635","article-title":"Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients","volume":"27","author":"Cappuzzo","year":"2009","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2023.101280_bib13","article-title":"Prognostic value of MET gene copy number and protein expression in patients with surgically resected non-small cell lung cancer: a meta-analysis of published literatures","volume":"9","author":"Guo","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.xcrm.2023.101280_bib14","doi-asserted-by":"crossref","first-page":"e512","DOI":"10.1016\/j.cllc.2020.11.002","article-title":"MET Amplification (MET\/CEP7 Ratio \u2265 1.8) Is an Independent Poor Prognostic Marker in Patients With Treatment-naive Non-Small-cell Lung Cancer","volume":"22","author":"Yin","year":"2021","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.xcrm.2023.101280_bib15","doi-asserted-by":"crossref","first-page":"5737","DOI":"10.1158\/1538-7445.AM2022-5737","article-title":"Abstract 5737: Precision oncology-driven real world clinical genomics data mining of MET alterations, TMB, and PD-L1 to empower indication agnostic patient enrollment and combination strategies","volume":"82","author":"Feng","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2023.101280_bib16","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1158\/2159-8290.CD-20-1500","article-title":"MET Amplification Attenuates Lung Tumor Response to Immunotherapy by Inhibiting STING","volume":"11","author":"Zhang","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2023.101280_bib17","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/annonc\/mdz167","article-title":"Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: Results from the IMMUNOTARGET registry","volume":"30","author":"Mazieres","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2023.101280_bib18","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.annonc.2020.03.293","article-title":"Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial","volume":"31","author":"Schuler","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2023.101280_bib19","series-title":"Non-Small Cell Lung Cancer Version 3.2022","year":"2022"},{"key":"10.1016\/j.xcrm.2023.101280_bib20","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1158\/1078-0432.CCR-19-2860","article-title":"First-in-man Phase I trial of the selective MET inhibitor tepotinib in patients with advanced solid tumors","volume":"26","author":"Falchook","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2023.101280_bib21","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s40265-020-01317-9","article-title":"Tepotinib: First Approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.xcrm.2023.101280_bib22","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa2004407","article-title":"Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations","volume":"383","author":"Paik","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2023.101280_bib23","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1158\/1078-0432.CCR-21-2733","article-title":"Tepotinib efficacy and safety in patients with MET exon 14 skipping NSCLC: Outcomes in patient subgroups from the VISION study with relevance for clinical practice","volume":"28","author":"Le","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2023.101280_bib24","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1158\/1078-0432.CCR-12-3247","article-title":"EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors","volume":"19","author":"Bladt","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2023.101280_bib25","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.lungcan.2021.11.020","article-title":"Brain penetration and efficacy of tepotinib in orthotopic patient-derived xenograft models of MET-driven non-small cell lung cancer brain metastases","volume":"163","author":"Friese-Hamim","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.xcrm.2023.101280_bib26","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/S2213-2600(20)30154-5","article-title":"Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b\/2, multicentre, randomised trial","volume":"8","author":"Wu","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.xcrm.2023.101280_bib27","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1158\/1078-0432.CCR-22-3318","article-title":"Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis","volume":"29","author":"Liam","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2023.101280_bib28","doi-asserted-by":"crossref","first-page":"S1419","DOI":"10.1016\/j.annonc.2022.08.054","article-title":"LBA52 - Tepotinib\u00a0+ osimertinib for EGFRm NSCLC with MET amplification (METamp) after progression on first-line (1L) osimertinib: Initial results from the INSIGHT 2 study","volume":"33","author":"Mazieres","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2023.101280_bib29","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1158\/1538-7445.AM2020-3385","article-title":"Abstract 3385: Liquid biopsy to detect MET exon 14 skipping (METex14) and MET amplification in patients with advanced NSCLC: Biomarker analysis from VISION study","volume":"80","author":"Le","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2023.101280_bib30","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.cllc.2022.03.002","article-title":"Safety of Tepotinib in Patients with MET Exon 14 Skipping NSCLC and Recommendations for Management","volume":"23","author":"Veillon","year":"2022","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.xcrm.2023.101280_bib31","doi-asserted-by":"crossref","first-page":"S1085","DOI":"10.1016\/j.jtho.2021.08.471","article-title":"P45.03 - Tepotinib in Patients with MET exon 14 (METex14) Skipping NSCLC as Identified by Liquid (LBx) or Tissue (TBx) biopsy","volume":"16","author":"Felip","year":"2021","journal-title":"J.\u00a0Thorac. Oncol."},{"key":"10.1016\/j.xcrm.2023.101280_bib32","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1158\/1078-0432.CCR-19-0306","article-title":"Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer","volume":"26","author":"Pairawan","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2023.101280_bib33","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/s41591-018-0134-3","article-title":"Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab","volume":"24","author":"Gandara","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2023.101280_bib34","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1053\/j.seminoncol.2019.10.002","article-title":"Baseline tumor size and survival outcomes in lung cancer patients treated with immune checkpoint inhibitors","volume":"46","author":"Hopkins","year":"2019","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.xcrm.2023.101280_bib35","doi-asserted-by":"crossref","first-page":"9021","DOI":"10.1200\/JCO.2021.39.15_suppl.9021","article-title":"Tepotinib in patients (pts) with advanced non-small cell lung cancer (NSCLC) with MET amplification (METamp)","volume":"39","author":"Le","year":"2021","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2023.101280_bib36","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/j.jtho.2021.06.017","article-title":"Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer","volume":"16","author":"Rolfo","year":"2021","journal-title":"J.\u00a0Thorac. Oncol."},{"key":"10.1016\/j.xcrm.2023.101280_bib37","doi-asserted-by":"crossref","first-page":"9012","DOI":"10.1200\/JCO.2021.39.15_suppl.9012","article-title":"METex14 ctDNA dynamics\u00a0& resistance mechanisms detected in liquid biopsy (LBx) from patients (pts) with METex14 skipping NSCLC treated with tepotinib","volume":"39","author":"Paik","year":"2021","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2023.101280_bib38","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.cllc.2022.07.002","article-title":"Oncogene Overlap Analysis of Circulating Cell-free Tumor DNA to Explore the Appropriate Criteria for Defining MET Copy Number\u2013Driven Lung Cancer","volume":"23","author":"Tsui","year":"2022","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.xcrm.2023.101280_bib39","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1158\/1078-0432.CCR-22-1749","article-title":"A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non\u2013Small Cell Lung Cancer (LC-SCRUM-Liquid)","volume":"29","author":"Sugimoto","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2023.101280_bib40","doi-asserted-by":"crossref","first-page":"LB078","DOI":"10.1158\/1538-7445.AM2022-LB078","article-title":"Abstract LB078: Tumor genomics in patients (pts) with advanced epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib therapy in the Phase II ORCHARD study","volume":"82","author":"Hartmaier","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2023.101280_bib41","doi-asserted-by":"crossref","first-page":"9074","DOI":"10.1200\/JCO.2023.41.16_suppl.9074","article-title":"Detection of MET amplification (METamp) in patients with EGFR mutant (m) NSCLC after first-line (1L) osimertinib","volume":"41","author":"Yu","year":"2023","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2023.101280_bib42","doi-asserted-by":"crossref","first-page":"LB294","DOI":"10.1158\/1538-7445.AM2023-LB294","article-title":"Abstract LB294: Baseline and on-treatment plasma-based genomics as a predictor of outcome in SAVANNAH: Savolitinib\u00a0+ osimertinib in EGFRm MET overexpressed\/amplified NSCLC post-osimertinib","volume":"83","author":"Hartmaier","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2023.101280_bib43","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1158\/2159-8290.CD-22-0586","article-title":"Osimertinib\u00a0+ Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor\u2013Mutated, MET-Amplified Non\u2013Small Cell Lung Cancer: TATTON","volume":"13","author":"Hartmaier","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2023.101280_bib44","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1158\/2767-9764.CRC-22-0438","article-title":"Detection of MET polysomy by next-generation sequencing and its clinical relevance for MET inhibitors","volume":"3","author":"Sun","year":"2023","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.xcrm.2023.101280_bib45","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1007\/s00432-022-04048-4","article-title":"Detection of MET amplification by droplet digital PCR in peripheral blood samples of non-small cell lung cancer","volume":"149","author":"Fan","year":"2023","journal-title":"J.\u00a0Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2023.101280_bib46","article-title":"Complementary Roles for Tissue- and Blood-Based Comprehensive Genomic Profiling for Detection of Actionable Driver Alterations in Advanced NSCLC","volume":"3","author":"Schwartzberg","year":"2022","journal-title":"JTO Clin. Res. Rep."},{"key":"10.1016\/j.xcrm.2023.101280_bib47","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41571-018-0058-3","article-title":"Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection","volume":"15","author":"Abbosh","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2023.101280_bib48","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.3390\/cancers14133275","article-title":"Circulating Tumor DNA-Based Genomic Profiling Assays in Adult Solid Tumors for Precision Oncology: Recent Advancements and Future Challenges","volume":"14","author":"Chan","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.xcrm.2023.101280_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140712","article-title":"Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA","volume":"10","author":"Lanman","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.xcrm.2023.101280_bib50","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1111\/1759-7714.12793","article-title":"Correlation between progression-free survival, tumor burden, and circulating tumor DNA in the initial diagnosis of advanced-stage EGFR-mutated non-small cell lung cancer","volume":"9","author":"Lee","year":"2018","journal-title":"Thorac. cancer"},{"key":"10.1016\/j.xcrm.2023.101280_bib51","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1002\/cncr.33118","article-title":"Association between circulating tumor DNA burden and disease burden in patients with ALK-positive lung cancer","volume":"126","author":"Zhang","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.xcrm.2023.101280_bib52","doi-asserted-by":"crossref","first-page":"CT158","DOI":"10.1158\/1538-7445.AM2021-CT158","article-title":"Abstract CT158: ctDNA analysis in the savolitinib phase II study in Non-Small Cell Lung Cancer (NSCLC) patients (pts) harboring MET exon 14 skipping alterations (METex14)","volume":"81","author":"Yu","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2023.101280_bib53","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.cllc.2022.07.012","article-title":"Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic Considerations","volume":"23","author":"Ahn","year":"2022","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.xcrm.2023.101280_bib54","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1007\/s00432-020-03267-x","article-title":"Comparison of liquid-based to tissue-based biopsy analysis by targeted next generation sequencing in advanced non-small cell lung cancer: a comprehensive systematic review","volume":"146","author":"Esagian","year":"2020","journal-title":"J.\u00a0Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2023.101280_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/biomedicines3010001","article-title":"Physiological Signaling and Structure of the HGF Receptor","volume":"3","author":"Baldanzi","year":"2014","journal-title":"Biomedicines"},{"key":"10.1016\/j.xcrm.2023.101280_bib56","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.21037\/tlcr-22-176","article-title":"MYC amplification-conferred primary resistance to capmatinib in a MET -amplified NSCLC patient: a case report","volume":"11","author":"Choi","year":"2022","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.xcrm.2023.101280_bib57","doi-asserted-by":"crossref","first-page":"57651","DOI":"10.18632\/oncotarget.10859","article-title":"Acquired savolitinib resistance in non-small cell lung cancer arises via multiple mechanisms that converge on MET-independent mTOR and MYC activation","volume":"7","author":"Henry","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.xcrm.2023.101280_bib58","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1158\/0008-5472.CAN-14-2743","article-title":"c-Myc alterations confer therapeutic response and acquired resistance to c-Met inhibitors in MET-addicted cancers","volume":"75","author":"Shen","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2023.101280_bib59","doi-asserted-by":"crossref","first-page":"6450","DOI":"10.1038\/s41467-021-26806-7","article-title":"Genomic signatures define three subtypes of EGFR-mutant stage II\u2013III non-small-cell lung cancer with distinct adjuvant therapy outcomes","volume":"12","author":"Liu","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2023.101280_bib60","doi-asserted-by":"crossref","first-page":"6377","DOI":"10.1038\/ncomms7377","article-title":"RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer","volume":"6","author":"Niederst","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2023.101280_bib61","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1200\/JCO.2016.71.9096","article-title":"Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas","volume":"35","author":"Lee","year":"2017","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2023.101280_bib62","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.lungcan.2020.11.016","article-title":"RB1 loss induced small cell lung cancer transformation as acquired resistance to pembrolizumab in an advanced NSCLC patient","volume":"151","author":"Arakawa","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.xcrm.2023.101280_bib63","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/j.jtho.2019.06.023","article-title":"Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In\u00a0Vitro","volume":"14","author":"Fujino","year":"2019","journal-title":"J.\u00a0Thorac. Oncol."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379123004743?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379123004743?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:59:32Z","timestamp":1770857972000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379123004743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":63,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S2666379123004743"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2023.101280","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort B","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2023.101280","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors.","name":"copyright","label":"Copyright"}],"article-number":"101280"}}